



Maintaining the Gold Standard



在线专家药物资讯平台

<http://www.clinicalpharmacology.com/>

Agenda

1. Clinical pharmacology 数据库简介
2. 第三方评测
3. 内容及功能介绍



Clinical Pharmacology – Goals/Features

Values:

1. 提供一站式药物资讯
2. 提高药剂师工作效率
3. 预防药物不良事件

Features:

1. 世界最大医学出版社Elsevier旗下权威产品；
2. 全球最大的药物咨询平台，及时、准确、权威的信息来源；
3. 提供来自4,300家药品制造商全球范围内121,000种药物商品名；
4. 全球超过10万药物专业人士的选择；
5. 临床相关，药物治疗方案紧贴实际操作；
6. 内容持续更新，界面简单、便于访问… …

Clinical Pharmacology - 功能



药物专论

Monographs

产品鉴别

Product Identification

药物对比

Drug Comparisons

产品对比

Product Comparisons

患者手册

Patient Education

药物相互作用

Drug Interactions

不良反应

Adverse Reactions

静脉注射相容性

IV Compatibility

药物计算器

Calculators

评测 - 2006年 美国诺瓦东南大学

目的:

针对信息范围、完整性、使用方便性和成本, 评估7种在线药物信息数据库

标准:

158 个问题

15 项数据库内容分类: 用量, 相互作用, 稳定性, 药理学和成本

结果: 综合排名

1. **Clinical Pharmacology**
2. Micromedex
3. Lexi- Comp
4. Facts and Comparisons
5. epocrates
6. RxList
7. ePocrates (free)




评测 - 2005年美国巴特勒大学·药学学院

测试

针对20项数据库内容分类的100个问题，对药物信息数据库的完整性、临床可靠性和使用方便性进行测试


Completeness Assessment

Total Number of Points Earned per Database -- 500 possible points



结论

Clinical Pharmacology 是最全面、最可信赖的药物信息资源



Homepage



[Home](#) [Help Me Now](#) [Contact Us](#) [Logout](#)



SEARCH

GO



Welcome, [liubaoyin](#)

REPORTS

FIND / LIST

PATIENT EDUCATION

RESOURCE CENTER

Welcome to Clinical Pharmacology!



Content Updates



Quick Reference Guides



Clinical Pharmacology Tutorials



Clinical Pharmacology Matters



Downloads


[Switch to the classic Clinical Pharmacology interface](#)

* The link to the Classic version of Clinical Pharmacology will no longer be available after August 31, 2008. Please see the [Tutorials section](#) for information regarding training and orientation for the new version.


控制面板 - Search



Home Help Me Now Contact Us Logout

 **CLINICAL**
pharmacology

SEARCH

Drug Identifier 

Welcome, [liubaoyin](#)

• **all** Monograph and Drug Product

RESOURCE CENTER

Search Results For: **amine**

Monographs (212)	US Drug Products (237)	Global Drug Names (340)
Indications (3)	Contraindications (1)	Overviews (1)

[Search 'amine' using phonetic search](#)

Monographs

- [Acetaminophen; Brompheniramine; Dextromethorphan; Pseudoephedrine](#)
- [Acetaminophen; Brompheniramine; Pseudoephedrine](#)
- [Acetaminophen; Caffeine; Chlorpheniramine; Hydrocodone; Phenylephrine](#)
- [Acetaminophen; Caffeine; Magnesium Salicylate; Phenyltoloxamine](#)
- [Acetaminophen; Caffeine; Phenyltoloxamine; Salicylamide](#)
- [Acetaminophen; Chlorpheniramine](#)
- [Acetaminophen; Chlorpheniramine; Dextromethorphan](#)
- [Acetaminophen; Chlorpheniramine; Dextromethorphan; Phenylephrine](#)
- [Acetaminophen; Chlorpheniramine; Dextromethorphan; Pseudoephedrine](#)
- [Acetaminophen; Chlorpheniramine; Phenylephrine](#)
- [Acetaminophen; Chlorpheniramine; Phenylephrine; Phenyltoloxamine](#)
- [Acetaminophen; Chlorpheniramine; Pseudoephedrine](#)

Copyright ©2008 Gold Standard

控制面板 - Search / 药品识别



Home Help Me Now Contact Us Logout

CLINICAL
pharmacology

SEARCH **GO**

Drug Identifier

Welcome, [liubaoyin](#)

REPORTS FIND / LIST PATIENT EDUCATION RESOURCE CENTER

Drug Identifier

Imprint / Marking:
Side 1:
Side 2:

Color:
- all -
all
amber
beige
black

Shape:
- all -
all
apple
bow-tie
bullet

Search

Hide Criteria ▲

Drug Identifier
7 Results Displaying 1-7

Lamotrigine 200mg Tablet Teva Pharmaceuticals USA Inc	white, diamond-shaped, side 1:PFIZER, side 2:VGR 50
Viagra 100mg Tablet NuCare Pharmaceuticals Inc	white, diamond-shaped, side 1:PFIZER, side 2:VGR 50
Viagra 100mg Tablet PD-RX Pharmaceuticals	white, diamond-shaped, side 1:PFIZER, side 2:VGR 50
Viagra 100mg Tablet Pfizer US Pharmaceuticals	white, diamond-shaped, side 1:PFIZER, side 2:VGR 50
Viagra 25mg Tablet Pfizer US Pharmaceuticals	white, diamond-shaped, side 1:PFIZER, side 2:VGR 50
Viagra 50mg Tablet PD-RX Pharmaceuticals	white, diamond-shaped, side 1:PFIZER, side 2:VGR 50
Viagra 50mg Tablet Pfizer US Pharmaceuticals	white, diamond-shaped, side 1:PFIZER, side 2:VGR 50

© 2005 GS

Copyright ©2008 Gold Standard

控制面板 - Report / 报告

Home Help Me Now Contact Us Logout

CLINICAL pharmacology

SEARCH GO

Drug Identifier

Welcome, [liubaoyin](#)

REPORTS FIND / LIST PATIENT EDUCATION RESOURCE CENTER

- Drug Interaction Report
- Product Comparison Report
- IV Compatibility Report
- Adverse Reaction Report
- Clinical Comparison Report
- Patent Report

Content Up

Reference Guides

pharmacology Tutorials

Clinical Pharmacology Matters

Downloads

[Switch to the classic Clinical Pharmacology interface](#)

* The link to the Classic version of Clinical Pharmacology will no longer be available after August 31, 2008. Please see the [Tutorials section](#) for information regarding training and orientation for the new version.

药物相互作用报告
产品对比报告
静脉注射相容性报告
不良反应报告
临床对比报告
药物专利报告

控制面板 - Find / List

Home Help Me Now Contact Us Logout

CLINICAL pharmacology

SEARCH GO

Drug Identifier

Welcome, liubaoyin

REPORTS FIND / LIST PATIENT EDUCATION RESOURCE CENTER

By Indication

By Contraindication/Precaution

By Adverse Reaction

By Multiple Criteria

By Classification

By NDC

By Manufacturer

Monographs A-Z

Investigational Monographs

CAM Monographs

Products with MedGuides

Boxed Warning Monographs

Interactions w/ Grapefruit Juice

Welcome

Content Updates

Pharmacology Matters

Drug Guides

Tutorials

Clinical Pharmacology interface

er A
form
y ver.

检索药物信息

1. 按适应证检索
2. 按禁忌证/预防检索
3. 按不良反应检索
4. 高级检索
5. 按药品管理分类检索
6. 按美国国家药品编码(NDC)检索
7. 按制造商检索

阅览药物专论

1. 按字母顺序阅览
2. 按在研药物阅览
3. 按 Medication Guides 阅览
4. 按Black Box 阅览

控制面板 — 患者教育 / 资源中心



Home Help Me Now Contact Us Logout

 **CLINICAL**
pharmacology

SEARCH **GO** 

Welcome, [liubaoyin](#)

REPORTS FIND / LIST **PATIENT EDUCATION** RESOURCE CENTER

- MedCounselor Sheet
- Manufacturer Contact Info
- Lab Reference Values
- Clinical Calculators**
- Drug Class Overviews

Welcome to Clinical Pharmacology

-  **Content Updates**
-  **Quick Reference Guides**
-  **Clinical Pharmacology Tutorials**

Pharmacology Matters

药物计算器
实验参考
药物分类
制造商信息


[Switch to the classic Clinical Pharmacology interface](#)

* The link to the Classic version of Clinical Pharmacology will no longer be available after August 31, 2008. Please see the [Tutorials section](#) for information regarding training and orientation for the new version.


控制面板 – 其他相关内容



Home Help Me Now Contact Us Logout

 **CLINICAL**
pharmacology


SEARCH **GO**


Drug Identifier 


Welcome, [liubaoyin](#)


REPORTS FIND / LIST PATIENT EDUCATION RESOURCE CENTER


Welcome to Clinical Pharmacology!

 Content **内容更新**

 Quick Reference **快速指导**

 Clinical Pharmacology Tutorials **使用指南**

 Clinical Pharmacology Matters **临床药物新闻**

 Downloads **下载**


[Switch to the classic Clinical Pharmacology interface](#)

* The link to the Classic version of Clinical Pharmacology will no longer be available after August 31, 2008. Please see the [Tutorials section](#) for information regarding training and orientation for the new version.


Report – Drug Interaction Report



Home Help Me Now Contact Us Logout

 **CLINICAL** pharmacology

SEARCH

Drug Identifier 

Welcome, [liubaoyin](#)

REPORTS FIND / LIST PATIENT EDUCATION RESOURCE CENTER

Drug Interaction Report


Product Comparison Report


IV Compatibility Report


Adverse Reaction Report


Clinical Comparison Report


Patent Report

 **Content Update**

 **Quick Reference Guides**

 **Clinical Pharmacology Tutorials**

 **Clinical Pharmacology Matters**


 **Downloads**

[Switch to the classic Clinical Pharmacology interface](#)

* The link to the Classic version of Clinical Pharmacology will no longer be available after August 31, 2008. Please see the [Tutorials section](#) for information regarding training and orientation for the new version.

Drug Interaction Report

Home Help Me Now Contact Us Logout

 **CLINICAL** pharmacology

SEARCH

Welcome, [liubaoyin](#)

REPORTS FIND / LIST PATIENT EDUCATION RESOURCE CENTER

Drug Interaction Report

Search for Drug, Select to Add to Report:

- Busulfex
- Cofex-DM
- Effexor
- Effexor XR
- Fexmid
- Fexofenadine**
- Fexofenadine Pseudoephedrine

Lifestyles: All

- Caffeine
- Enteral Feedings
- Ethanol
- Food
- Grapefruit Juice
- Tobacco

Drug List:

- Cetrizine

Type: Professional Consumer

检索药物名称

选择患者生活习惯

查看报告

Drug Interaction Report



SEARCH

GO

Drug Identifier



Welcome, [liubaoyin](#)

REPORTS

FIND / LIST

PATIENT EDUCATION

RESOURCE CENTER

Drug Interaction Report



Drug Interaction Report for Healthcare Professionals

Show Report Criteria ▼

● Collapse All Sections

For the following 2 medications:

- Cetirizine
- Fexofenadine

Also with: Caffeine, Ethanol, Grapefruit Juice

- Level 1 (Severe) (no results)
- Level 2 (Major) (1 result)

Drug to Drug Interactions

Cetirizine and Ethanol


Cetirizine adds to the effect that ethanol [\[6341\]](#) has on CNS depression, but it apparently does not potentiate the effects of ethanol. Additive drowsiness may occur if cetirizine is administered with other drugs that depress the CNS. [\[5607\]](#) Cetirizine should be used with caution with barbiturates, benzodiazepines, buprenorphine, butorphanol, dronabinol, THC, entacapone, general anesthetics, haloperidol, nabilone [\[9044\]](#), nalbuphine, opiate agonists,

Copyright ©2008 Gold Standard


Report – Product Comparison Report



[Home](#) [Recent Reports](#) [Help Me Now](#) [Contact Us](#) [Logout](#)



GO



Welcome, [liubaoyin](#)

REPORTS

FIND / LIST

PATIENT EDUCATION

RESOURCE CENTER

Drug Interaction Report
Product Comparison Report
IV Compatibility Report

Product Comparison Report

Report Options:

- Access Pre
- Search By
- Search By

Product Comparison Report Show Report Criteria ▼

Analgesic and Antihistamine Combinations
 Products that contain antihistamines and analgesics - typically used for sleep

Filters: Flavor --- Form --- Other Attributes --- Apply

Product	Flavor	Form	Strength	Sedating Blockers	Additional Info
Aceta-Gesic Tablet	bubblegum orange vanilla	Effervescent tablet Oral capsule Oral powder Oral solution Oral suspension Oral tablet Oral tablet, extended release Oral tablet, gastro-resistant	325 mg	Phenyltol Citrate 3	alcohol-free Do Not Crush or Chew dye-free gluten-free phenylketonuric sodium-free sugar/sucrose-free
Acetaminophen/Diphenhydramine 500 mg Tablet			500 mg	Diphenhy Hydrochloride 25 mg	
Diabetic Tussin Nighttime Solution			Acetaminophen 325 mg	Diphenhydramine Hydrochloride 12.5 mg	Dextromethorphan Hydrobromide orange alcohol-free dye-free phenylketonuric sodium-free sugar/sucrose-free Oral solution


Predefined


- [Analgesi](#)
Products
- [Analgesi](#)
All produ
- [Analgesi](#)
List of co
- [Analgesi](#)
All produ
- [Analgesi](#)
All produ
- [Analgesi](#)
Natur

Report – IV Compatibility Report



Home Recent Reports Help Me Now Contact Us Logout

 **CLINICAL**
pharmacology

SEARCH 

Welcome, [liubaoyin](#)

REPORTS FIND / LIST PATIENT EDUCATION RESOURCE CENTER

IV Compatibility Report


Search for IV Drug, Select to Add

Drug List:

Group Report By: Route Compatibility

[Hide Report Criteria ▲](#)


Copyright ©2008 Gold Standard

 **CLINICAL**
pharmacology


IV Compatibility Report



Home Recent Reports Help Me Now Contact Us Logout

 **CLINICAL** pharmacology

SEARCH

[Drug Identifier](#) 

Welcome, [liubaoyin](#)

REPORTS FIND / LIST PATIENT EDUCATION RESOURCE CENTER

IV Compatibility Report

Search for IV Drug, Select to Add to Report: Drug List: [Clear Criteria](#)

 Aminophylline

IV Compatibility Report

IV Compatibility Report for:

- Aminophylline
- Lidocaine HCl (Xylocaine®)

When mixed in solution:

Aminophylline and **Lidocaine HCl (Xylocaine®)** are compatible when mixed in solution.

- The products are physically compatible for at least 20 to 24 hrs in D5W and LR and Sodium Chloride 0.9% (normal saline, NS) at 25 degrees C

NOTE: Combinations that do not appear in this report reflect a lack of clinical data.

Copyright ©2008 Gold Standard

Adverse Reactions Report

Adverse Reactions Report



Show Report Criteria ▼

Adverse Reactions Report for:

- Gefitinib
- Fexofenadine

2 of these drugs may cause:

Adverse Reaction	Associated Drugs
angioedema	Fexofenadine Gefitinib
cough	Fexofenadine Gefitinib
diarrhea	Fexofenadine Gefitinib
fever	Fexofenadine Gefitinib
nausea/vomiting	Fexofenadine Gefitinib
pruritus	Fexofenadine

1 drug may cause:

Adverse Reaction	Associated Drug
acneiform rash	Gefitinib
amblyopia	Gefitinib
anaphylactoid reactions	Fexofenadine
anorexia	Gefitinib
asthenia	Gefitinib
back pain	Fexofenadine
bleeding	Gefitinib
bullous rash	Gefitinib
conjunctivitis	Gefitinib
corneal erosion	Gefitinib
dehydration	Gefitinib
dizziness	Fexofenadine
drowsiness	Fexofenadine
dysmenorrhea	Fexofenadine
dyspepsia	Fexofenadine
dyspnea	Gefitinib

Copyright ©2008 Gold

Clinical Comparison Report

Clinical Comparison Report

Add Drugs To Report:

- By Name
 By Classification

Add

Add Topics To Report:

- Indications
 Contraindications / Precautions
 Adverse Reactions

NOTE: Topics are filtered by drug list

Select All

- breast-feeding
- dialysis
- driving or operating machinery
- elderly
- ethanol intoxication
- hepatic disease

Add

Drug List:

Clear List

Cetirizine

Topic List:

Clear Topics

allergic rhinitis
 atopic dermatitis
 urticaria

Run Report

Hide Report Criteria ▲

Copyright ©2008 Gold Standard

Clinical Comparison Report

Clinical Comparison Report



Show Report Criteria ▼

	Fexofenadine	Cetirizine
Can be used for allergic rhinitis ?	Yes	Yes
Can be used for atopic dermatitis ?	No	Yes†
Can be used for urticaria ?	Yes	Yes

Produces adverse reactions

Is contraindicated in dialysis?

Is contraindicated in ethanol?

† non-FDA

Cetirizine

Description/Classification	Mechanism of Action	Pharmacokinetics
Indications/Dosage	Administration	Contraindications/Precautions
Pregnancy/Breast-feeding	Interactions	Adverse Reactions
How Supplied	Monitoring Parameters	Global Drug Names

Indications List

Children < 6 years: Safe and effective use has not been established.

For the treatment of **atopic dermatitis**†:

Oral dosage:

Adults: Dosage information is not available.

Children 6–12 years: Limited data from 1 small trial suggest the use of 5–10 mg PO once daily may be beneficial. [\[10539\]](#) This double blind trial of 22 children ages 6–12 years compared cetirizine to placebo for 8 weeks and found an improvement in symptoms in both groups. However, the authors report a more rapid reduction in symptoms in the cetirizine group. Additional medications were required by significantly fewer patients in the cetirizine group (18% vs. 82%).

Children 1–2 years: Limited data suggest 0.25 mg/kg PO twice daily may be beneficial for some patients. [\[10540\]](#) One randomized, double blind trial compared cetirizine to placebo in 817 children ages 1–2 years with symptoms of active atopic dermatitis. After 18 months of treatment, the severity of symptoms as rated by the SCORAD scale decreased in both the placebo and treatment groups. There was no statistically significant difference between the 2 groups. However, other oral antihistamines were used to a greater extent in the placebo group which may confound the results. In the sub-group analysis

Copyright ©2008 Gold Standard

Hide Sections ▲

Patent Report

Patent Report

Find Active Patent and/or Exclusivity Information:

- By Drug Name
 By Expiration Date

Search for Drug Product:


[Hide Report Criteria](#) ▲

Results For: Fexofenadine

Product Name	Marketer Name	Patent Number	Code	Expiration Date ▲
Fexofenadine Hydrochloride 180mg Tablet	Prasco Laboratories		D-101	10/13/2008
Fexofenadine Hydrochloride 180mg Tablet	Prasco Laboratories	6187791	U-138	05/11/2012
Fexofenadine Hydrochloride 180mg Tablet	Prasco Laboratories	6187791	U-684	05/11/2012
Fexofenadine Hydrochloride 180mg Tablet	Prasco Laboratories	6399632	U-468	05/11/2012
Fexofenadine Hydrochloride 180mg Tablet	Prasco Laboratories	6399632	U-684	05/11/2012
Fexofenadine Hydrochloride 30mg Tablet	Prasco Laboratories	6187791	U-138	05/11/2012
Fexofenadine Hydrochloride 30mg Tablet	Prasco Laboratories	6187791	U-684	05/11/2012
Fexofenadine Hydrochloride 30mg Tablet	Prasco Laboratories	6399632	U-468	05/11/2012
Fexofenadine Hydrochloride 30mg Tablet	Prasco Laboratories	6399632	U-684	05/11/2012

Copyright ©2008 Gold Standard


Find/List – by Indication



Home Recent Reports Help Me Now Contact Us Logout

CLINICAL pharmacology

SEARCH GO

Drug Identifier 

Welcome, **liubaoyin**

REPORTS FIND / LIST PATIENT EDUCATION RESOURCE CENTER

By Indication

- By Contraindication/Precaution
- By Adverse Reaction
- By Multiple Criteria
- By Classification
- By NDC
- By Manufacturer

Find Drugs By Indication

Search for Indication, Select to Find:

Find

(example: heart failure)

Drugs indicated for heart failure:

Amiloride

Description/Classification	Mechanism of Action	Pharmacokinetics
Indications/Dosage	Administration	Contraindications/Precautions
Pregnancy/Breast-feeding	Interactions	Adverse Reactions
How Supplied	Monitoring Parameters	Global Drug Names

Indications List

Hide Sections

For the adjunctive treatment of heart failure (peripheral edema), hypertension, or hypokalemia:

NOTE: Amiloride rarely should be used alone due to its weak diuretic and antihypertensive effects and its associated risk of hyperkalemia (10% when used as a single agent). Amiloride is indicated as adjunctive treatment with thiazide or loop diuretics to treat heart failure or hypertension, when it is clinically important to prevent hypokalemia or when persistent hypokalemia has been documented.

Oral dosage:

Adults: Initially, 5–10 mg/day PO. Titrate the dosage to achieve clinical goals; carefully monitor serum potassium and electrolyte balance. The maximum dosage is 20 mg/day as recommended by the manufacturer; however, doses of 40 mg/day have been used. The plateau of diuretic effect is reached at doses > 40 mg/day.

Adolescents: Initially, 5–20 mg/day PO for diuresis. [1526] The maximum recommended dosage by the manufacturer is 20 mg/day PO. Up to 40 mg/day PO has been used in adolescent patients. [1526]

Elderly: See adult dosage. Elderly patients may be more sensitive to the diuretic effects of the drug and are more likely to have age-associated renal dysfunction (see dosage for patients with renal impairment).

Copyright ©2008 Gold Standard

Start a multiple criteria report using these results

Find/List – by Multiple Criteria

Find By Multiple Criteria

And
 Or

Is Indicated for:
 Is NOT Indicated for:
 Is Contraindicated/Precautioned in:
 Is NOT Contraindicated/Precautioned in:
 Causes an Adverse Reaction of:
 Does NOT Cause an Adverse Reaction of:

Search For Term, Click to Add to List:

(example: heart failure)

Drugs Satisfy

- Is Indicat
- And Is NC
- And Caus
- [Candesart](#)
- [Losartan](#)
- [Nesiritide](#)
- [Quinapril](#)
- [Valsartan](#)

Find By Multiple Criteria

Drugs Satisfying the Following Criteria:

[Add New Criteria](#)

[Start New Report](#)

- Is Indicated for: heart failure
- And Is NOT Indicated for: diabetes mellitus
- And Causes an Adverse Reaction of: back pain
- And Does NOT Cause an Adverse Reaction of: nephrolithiasis
- [Candesartan](#)
- [Losartan](#)
- [Nesiritide, BNP](#)
- [Quinapril](#)
- [Valsartan](#)

Find – By Manufacturer



Find Products by Manufacturer

0-9 A B C D E F G H I J K L M N O **P** Q R S T U V W X Y Z

Hide Criteria ▲

- [Peginoi](#)
- [Pegasus](#)
- [Penn](#)
- [Performanc](#)
- [Perrigo](#)
 - [Perrigo Pharmaceuticals Company](#)
 - [Perrigo Rx](#)
- [Perry Med](#)
- [Personal](#)
- [PersonCovy](#)
- [PF Labs](#)
- [Pfizer](#)
 - [Pfizer Consumer Healthcare](#)
 - [Pfizer Pharmaceuticals Inc](#)
 - [Pfizer Pharmaceuticals Ltd](#)
 - [Pfizer US Pharmaceuticals](#)
 - [Pfizer US Pharmaceuticals](#)

Copyright ©2008 Gold Standard

Pfizer - Viagra



Find Products by Manufacturer

0-9 A B C D E F G H I J K L M N O **P** Q R S T U V W X Y Z

Hide Criteria ▲

- [Vagifem 25mcg Vaginal Tablet](#) (off market)
- [Vantin 100mg Tablet](#)
- [Vantin 100mg/5ml Powder for Suspension](#) (off market)
- [Vantin 200mg Tablet](#)
- [Vantin 50mg Sildenafil](#)
- [Vfend 200mg](#)
- [Vfend 200mg](#)
- [Vfend 40mg](#)
- [Vfend 50mg](#)
- [Viagra 100mg](#)
- [Viagra 25mg](#)
- [Viagra 50mg](#)
- [Vibra-Tabs](#)
- [Vibramycin](#)
- [Vibramycin](#)
- [Vibramycin](#)
- [Vibramycin](#)
- [Vibramycin](#)
- [Vibramycin](#)

Sildenafil

- Description/Classification
- Indications/Dosage
- Pregnancy/Breast-feeding
- How Supplied

Active Ingredients:
Drug Description:
Inactive Ingredients:



© 2005 GS

Magnesium Stearate
Microcrystalline Cellulose
Titanium Dioxide
Triacetin

Hide Sections ▲


Drug Photo


Copyright ©2008 Gold Standard

Monographs



Home Recent Reports Help Me Now Contact Us Logout

 **CLINICAL** pharmacology

SEARCH 

Welcome, [liubaoyin](#)

REPORTS FIND / LIST PATIENT EDUCATION RESOURCE CENTER

By Indication
By Contraindication/Precaution
By Adverse Reaction
By Multiple Criteria
By Classification
By NDC
By Manufacturer

Monographs A-Z
Investigational Monographs
CAM Monographs
Products with MedGuides
Boxed Warning Monographs
Interactions w/ Grapefruit Juice

List of Monographs A-Z

0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

G

- [Gabapentin](#)
- [Gaboxadol](#)
- [Gadopentetate](#)
- [Galantamine](#)
- [Gallium](#)
- [Galsulfase](#)
- [Gamma-linolenic acid, GLA](#)
- [Ganaxolone](#)
- [Ganciclovir](#)
- [Ganirelix](#)
- [Garenoxacin](#)
- [Garlic, Allium sativum](#)
- [Gatifloxacin](#)
- [Gefitinib](#)
- [Gemcitabine](#)
- [Gempfibrozil](#)

Hide Criteria ▲

Copyright ©2008 Gold Standard

View Monographs

Gefitinib

View Drug Monograph - Gefitinib

- [Description/Classification](#)
- [Mechanism of Action](#)
- [Pharmacokinetics](#)
- [Indications/Dosage](#)
- [Administration](#)
- [Contraindications/Precautions](#)

Gefitinib

Gefitinib		
Description/Classification	Mechanism of Action	Pharmacokinetics
Indications/Dosage	Administration	Contraindications/Precautions
Pregnancy/Breast-feeding	Interactions	Adverse Reactions
How Supplied	Monitoring Parameters	Global Drug Names

Hide Sections ▲

Chile

- Iressa® - (AstraZeneca)

China

- Iressa® - (AstraZeneca)

Georgia

- Iressa® - (AstraZeneca)

Hong Kong

Copyright ©2008 Gold Standard

Monographs - Contraindications

Gefitinib

Description/Classification	Mechanism of Action	Pharmacokinetics
Indications/Dosage	Administration	Contraindications/Precautions
Pregnancy/Breast-feeding	Interactions	Adverse Reactions
How Supplied	Monitoring Parameters	Global Drug Names

Contraindications / Precautions List

B Indicates Black Box Warning

Absolute Contraindications:

breast-feeding

Precautions

chemotherapy

children

females

Gefitinib has also been shown

Gefitinib is classified as FDA pregnancy category X. It is contraindicated in a woman who is pregnant. There is also a risk of fetal harm if a patient becomes pregnant or if a patient becomes pregnant while receiving gefitinib.

Gefitinib

Contraindications / Precautions List

Show Sections ▼



It is not known if gefitinib is excreted in human breast milk. In animal studies, levels of gefitinib and its metabolites were 11- to 19-fold higher in milk than in blood. Because of the potential for serious adverse reactions in the nursing infant, women should be advised against **breast-feeding** while receiving gefitinib therapy.

Gefitinib exposure may be increased in patients with hepatic disease. In patients with liver metastases and moderately to severely elevated liver enzymes, gefitinib pharmacokinetics were similar to those of individuals without liver abnormalities. Gefitinib has been associated with elevated hepatic enzymes; therefore, periodic liver function (transaminases, bilirubin, and alkaline phosphatase) testing should

Copyright ©2008 Gold Standard

Monographs - Black Box Warning



Welcome, [liubaoyin](#) **REPORTS** **FIND / LIST** **PATIENT EDUCATION** **RESOURCE CENTER**

By Indication By Contraindication/Precaution

List of Boxed Warning Monographs (a.k.a. Fentanyl)

Description/Classification	Mechanism of Action	Pharmacokinetics
Indications/Dosage	Administration	Contraindications/Precautions
Pregnancy/Breast-feeding	Interactions	Adverse Reactions
IV Compatibility	How Supplied	Monitoring Parameters
Global Drug Names		

Contraindications / Precautions List

- B** Indicates Black Box Warning
- Absolute Contraindications**
- B** **accidental exposure**
- Precautions**
- abrupt discontinuation
- alcoholism

Specifically question patients or caregivers about the presence of children in the home and counsel them regarding the dangers to children from **accidental exposure**. Fentanyl patches contain fentanyl in an amount that can be fatal to a child or pet. Keep patches out of reach of children. In the event that an Actiq® unit is not completely removed, remove it as soon as possible. Used fentanyl patches still may contain enough fentanyl to be fatal if out of the reach of children or pets. Also, do not use a patch that is leaking or damaged in any way. Direct exposure to the fentanyl gel may lead to serious adverse events such as respiratory depression and fatal overdose. Immediately dispose of patches that may be damaged or compromised in any way by flushing them down the toilet. If gel accidentally contacts the skin, thoroughly rinse exposed skin with large amounts of water; do not use soap, alcohol, or other solvents to remove the gel because they may enhance the drug's ability to penetrate the skin.

Copyright ©2008 Gold Standard

Monograph - image



Fentanyl

Description/Classification
Indications/Dosage
Pregnancy/Breast-feeding
IV Compatibility
Global Drug Names

Fentanyl 50mcg/1h

Duragesic 50mcg/1h (Janssen-Cilag Inc)
Duragesic 50mcg/1h (Sub OMP)
Fentanyl 50mcg/hr Transdermal Patch (Actavis South Atlantic LLC)
Fentanyl 50mcg/hr Transdermal Patch (Mylan Pharmaceuticals Inc)
Fentanyl 50mcg/hr Transdermal Patch (Sandoz Inc)
Fentanyl 50mcg/hr Transdermal Patch (STADA Pharmaceuticals Inc) (off market)

© 2005 GS

Copyright ©2008 Gold Standard

NDC 0781-7112-55
Fentanyl Transdermal System
50 mcg/h
In vivo delivery of 50 mcg/h fentanyl for 72 hours
NOT FOR ACUTE OR POSTOPERATIVE USE
Each transdermal system contains:
5 mg fentanyl and 0.2 mL alcohol USP
DO NOT USE IF SEAL ON POUCH IS BROKEN
KEEP OUT OF REACH OF CHILDREN
Rx only
Five (50 mcg/h) Systems
00143771
SANDOZ

NDC 0781-7112-55
Fentanyl Transdermal System
50 mcg/h
In vivo delivery of 50 mcg/h fentanyl for 72 hours
NOT FOR ACUTE OR POSTOPERATIVE USE
Each transdermal system contains:
5 mg fentanyl and 0.2 mL alcohol USP
KEEP OUT OF REACH OF CHILDREN
Rx only One (50 mcg/h) System
00143771
SANDOZ
ATTENTION: ONLY FOR USE BY PATIENT FOR WHOM PRESCRIBED.

List – Interactions with Grapefruit Juice



List of Interactions with Grapefruit Juice

0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

G

- [Gefitinib](#)
- [Green Tea](#)
- [Guarana](#)

Gefitinib		
Description/Classification	Mechanism of Action	Pharmacokinetics
Indications/Dosage	Administration	Contraindications/Precautions
Pregnancy/Breast-feeding	Interactions	Adverse Reactions
How Supplied	Monitoring Parameters	Global Drug Names

H

- [Halofantrine](#)

I

- [Imatinib](#)
- [Indinavir](#)
- [Isradipine](#)
- [Itraconazole](#)
- [Ixabepipron](#)

Interactions List

therefore caution should be used when administering CYP3A4 inhibitors with gefitinib. [5012] The following are drugs that may inhibit CYP3A4: amiodarone, clarithromycin, conivaptan [8569], dalfopristin; quinupristin, delavirdine, efavirenz, erythromycin, fluvoxamine, fluoxetine, **grapefruit juice**, imatinib, STI-571, mifepristone, RU-486, nefazodone and selected azole antifungals. [4718] (NOTE: This list may not be inclusive of all agents that may inhibit CYP3A4.) In addition, because gefitinib inhibits CYP2D6 to some degree, the metabolism of some of the listed agents may be decreased by gefitinib. [5012]

Clozapine is contraindicated for use with other drugs with a well known risk of suppressing bone marrow function [4989], such as antineoplastic agents. Concomitant use of clozapine with other drugs known to cause bone marrow depression might increase the possibility of developing myelosuppression. Additionally, clozapine is a CYP2D6 substrate. Gefitinib (at the highest concentration, 5000 ng/ml) inhibits CYP2D6 by 43%; coadministration is expected to result in elevated clozapine serum concentrations and severe adverse reactions. [5012]

Hide Sections ▲

Copyright ©2008 Gold Standard

患者教育 — MedCounselor



CLINICAL pharmacology

SEARCH **GO** **Drug Identifier**

Welcome, **liubaoyin** **REPORTS** **FIND / LIST** **PATIENT EDUCATION** **RESOURCE CENTER**

MedCounselor Sheets **Show Search Box**

Search

Gefitinib Oral tablet

Trade Names

Iressa

The list of names may not include all products that are available on the market.

What is this medicine?
GEFITINIB is a chemotherapy drug. It targets a specific enzyme within cancer cells and stops the cancer cells from growing. It is used to treat advanced non-small cell lung cancer. To receive this medicine, you will be enrolled in the Iressa Access Program. The medicine will be provided by a special mail-order pharmacy.

This medicine may be used for other purposes; ask your health care provider or pharmacist if you have questions.

What should I tell my health care provider before I take this medicine?
They need to know if you have any of these conditions:



Copyright ©2008 Gold Standard

Copyright ©2008 Gold Standard

CLINICAL pharmacology

资讯中心 — 制造商信息



Welcome, [liubaoyin](#) [REPORTS](#) [FIND / LIST](#) [PATIENT EDUCATION](#) [RESOURCE CENTER](#)

Manufacturer Contact Info

[3](#) [7](#) [A](#) [B](#) [C](#) [D](#) [E](#) [F](#) [G](#) [H](#) [I](#) [J](#) [K](#) [L](#) [M](#) [N](#) [O](#) [P](#) [Q](#) [R](#) [S](#) [T](#) [U](#) [V](#) [W](#) [X](#)

- 3**
 - 3M Pharmaceuticals Inc**
- 7**
 - 7 Oaks Pharmaceutical Corp
- A**
 - A G Marin Pharmaceutical
 - A&Z Pharmaceutical, Inc.
 - A. Aarons a Sub of Bradley Pharmaceuticals, Inc.
 - A. Aarons a Subsidiary of Bradley Pharmaceuticals, Inc.
 - AAI Development Services


3M Pharmaceuticals Inc

3M Center 275-3W-01
St Paul, MN 55144-100
800-328-0255

Copyright ©2008 Gold Standard

资讯中心 — Lab Reference Values



 **CLINICAL** pharmacology

SEARCH [GO](#)

[Drug Identifier](#)

Welcome, [liubaoyin](#)

REPORTS [FIND / LIST](#) [PATIENT EDUCATION](#) [RESOURCE CENTER](#)

Manufacturer Contact Info

Lab Reference Values

Clinical Calculators

Drug Class Overviews

Lab Test Listings

Arterial Blood Gas Panel [View All](#)

- Bicarbonate (arterial), whole blood
- Carbon Dioxide, Partial Pressure (pCO₂) (arterial), whole blood
- Oxygen, Partial Pressure (pO₂) (arterial), whole blood
- pH (arterial), whole blood

Coagulation Panel [View All](#)

- Activated Clotting Time (Activated Coagulation Time, ACT), whole blood
- Bleeding Time (BT)
- Fibrinogen**
- Partial Thromboplastin Time - activated

Copyright ©2008 Gold Standard

资讯中心 — Lab Reference Values



Lab Test Listings



Laboratory Test Summary


Fibrinogen

Population	Traditional Units	Scientific International Units	Comments
All	150-400 mg/dL	1.5-4 g/L	Clauss method; reference range may be dependent on reagent-instrument combination; each laboratory should establish reference intervals.


Copyright ©2008 Gold Standard

Clinical Calculators



 **CLINICAL** pharmacology

SEARCH





Welcome, [liubaoyin](#)


REPORTS FIND / LIST PATIENT EDUCATION RESOURCE CENTER


- Manufacturer Contact Info
- Lab Reference Values
- Clinical Calculators**
- Drug Class Overviews


Welcome to Clinical Pharmacology!

 [Content Updates](#)

 [Quick Reference Guides](#)

 [Clinical Pharmacology Tutorials](#)

 [Clinical Pharmacology Matters](#)

 [Downloads](#)

[Switch to the classic Clinical Pharmacology interface](#)

* The link to the Classic version of Clinical Pharmacology will no longer be available after August 31, 2008. Please see the [Tutorials section](#) for information regarding training and orientation for the new version.

Clinical Calculators – DC & BMI



General Dosing Calculators

[Weight-based Dosage Calculator](#)

[Body Surface Area \(BSA\)](#)

[Body Mass Index \(BMI\)](#)

[Weight Conversion Calculator](#)

[Ideal Body Weight \(IBW\)](#)

[Creatinine Clearance](#)

http://clinicalpharmacology.com - Weight Based Dosage Calculator - Microsoft I...

Weight Based Dosage Calculator [View all calculators](#) | [Print](#)

Patient's Weight: kg lb

http://clinicalpharmacology.com - Body Mass Index Calculator - Microsoft Internet Explorer

Body Mass Index Calculator [View all calculators](#) | [About Calculations](#) | [Print](#)

Patient's Weight: kg lb

Patient's Height: in cm

Result: Body Mass Index = 24.21 kg/m²


Clinical Pharmacology Copyright © 2008
Gold Standard

Internet


[Epidural Formulation Calculator](#)

Drug Class Reviews





SEARCH

Drug Identifier 

Welcome, [liubaoyin](#)

REPORTS FIND / LIST PATIENT EDUCATION RESOURCE CENTER

Manufacturer Contact Info

Drug Class Overviews

Antifungals

History: Since the advent of penicillin in 1941, dozens of antimicrobials have been developed by the pharmaceutical companies. Among these, the antifungal agents have been studied extensively and no less than 20 agents are used clinically. Antifungal agents are divided into several classes and can be distinguished by their site of action in fungal cells. Those used clinically include polyenes; nucleoside analogues (fluorinated pyrimidines); azoles; echinocandins (includes pneumocandins); allylamines, benzylamines, and thiocarbamates; nucleoside analogs, and sulfonamides. These agents can be further divided into two categories: those used for treating systemic mycotic infections and those for treating superficial mycotic infections (includes dermatophytic infections and candidosis). Dermatophytic infections involve the hair, nails, and skin, whereas candidosis (usually associated with *Candida albicans*) affects moist skin and mucous membranes such as the GI tract and vagina. Investigational classes of antifungal agents include nikkomycins, pradimicins-benanomcins, sordarins, and others.

Topical and vaginal antifungal agents were in use prior to the systemic antifungals we see used clinically today. These agents include sulfanilamide and undecylenic acid. Sulfanilamide, a sulfonamide, has been around since 1939. It is only administered intravaginally for the treatment of vulvovaginal candidiasis. Undecylenic acid and undecylenate salts (e.g., calcium undecylenate, copper undecylenate, zinc undecylenate) are topical antifungal agents used primarily for tinea pedis, tinea cruris, and other skin infections caused by dermatophytic fungi (e.g., ringworm). Undecylenic acid and undecylenate salts were approved by the FDA in 1946.

Copyright ©2008 Gold Standard



谢谢